{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:23:16Z","timestamp":1792686196235,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jacadv.2025.101757","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T21:20:58Z","timestamp":1746825658000},"page":"101757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"P1","title":["Stroke Prevention With Oral Anticoagulants in High-Risk Atrial Fibrillation in an Aging Population"],"prefix":"10.1016","volume":"4","author":[{"given":"Ken","family":"Okumura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2348-7646","authenticated-orcid":false,"given":"Masaharu","family":"Akao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4769-5925","authenticated-orcid":false,"given":"Shinya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2025.101757_bib1","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacadv.2025.101757_bib2","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/ehjqcco\/qcaa061","article-title":"Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990-2017: results from the Global Burden of Disease Study 2017","volume":"7","author":"Dai","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"35","key":"10.1016\/j.jacadv.2025.101757_bib3","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1093\/eurheartj\/eht280","article-title":"Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060","volume":"34","author":"Krijthe","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.101757_bib4","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/europace\/euz141","article-title":"Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: the FAI Project","volume":"21","author":"Di Carlo","year":"2019","journal-title":"Europace"},{"key":"10.1016\/j.jacadv.2025.101757_bib5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cger.2022.05.004","article-title":"Polypharmacy in older adults","volume":"38","author":"Canio","year":"2022","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.jacadv.2025.101757_bib6","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.jacadv.2025.101757_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.101757_bib8","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jocn.2020.10.036","article-title":"Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: an in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial","volume":"86","author":"Nelson","year":"2021","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.jacadv.2025.101757_bib9","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1161\/STROKEAHA.112.650614","article-title":"Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial","volume":"43","author":"Hart","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.jacadv.2025.101757_bib10","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/STROKEAHA.113.004506","article-title":"Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban","volume":"45","author":"Hankey","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.jacadv.2025.101757_bib11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ahj.2016.01.005","article-title":"History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation trial","volume":"175","author":"De Caterina","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacadv.2025.101757_bib12","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.jacc.2014.02.549","article-title":"Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin","volume":"63","author":"Hylek","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2025.101757_bib13","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.jacc.2016.03.004","article-title":"Knowledge gaps in cardiovascular care of the older adult population: a scientific statement from the American Heart Association, American College of Cardiology, and American Geriatrics Society","volume":"67","author":"Rich","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2025.101757_bib14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.anclin.2019.04.007","article-title":"Geriatric pharmacology: an update","volume":"37","author":"Andres","year":"2019","journal-title":"Anesthesiol Clin"},{"key":"10.1016\/j.jacadv.2025.101757_bib15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/17425255.2023.2287472","article-title":"Pharmacokinetics and pharmacodynamics of direct oral anticoagulants","volume":"19","author":"Hindley","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jacadv.2025.101757_bib16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/gerona\/glr118","article-title":"Drug metabolism in older people\u2013a key consideration in achieving optimal outcomes with medicines","volume":"67","author":"McLachlan","year":"2012","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jacadv.2025.101757_bib17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev.pa.32.040192.001415","article-title":"Geriatric pharmacology: basic and clinical considerations","volume":"32","author":"Tumer","year":"1992","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jacadv.2025.101757_bib18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40262-023-01222-w","article-title":"Insights into the pharmacokinetics and pharmacodynamics of direct oral anticoagulants in older adults with atrial fibrillation: a structured narrative review","volume":"62","author":"Edwina","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jacadv.2025.101757_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pr.56.2.4","article-title":"Aging biology and geriatric clinical pharmacology","volume":"56","author":"McLean","year":"2004","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jacadv.2025.101757_bib20","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s40262-022-01108-3","article-title":"Population pharmacokinetics of rivaroxaban in Chinese patients with non-valvular atrial fibrillation: a prospective multicenter study","volume":"61","author":"Zhang","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jacadv.2025.101757_bib21","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bcp.12114","article-title":"Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects","volume":"76","author":"Upreti","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacadv.2025.101757_bib22","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/jgs.16992","article-title":"Muscle mass and direct oral anticoagulant activity in older adults with atrial fibrillation","volume":"69","author":"Bendayan","year":"2021","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jacadv.2025.101757_bib23","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/jamainternmed.2016.3057","article-title":"Risk of bleeding and thrombosis in patients 70 years or older using vitamin K antagonists","volume":"176","author":"Kooistra","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacadv.2025.101757_bib24","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003432","article-title":"Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 Trial","volume":"5","author":"Kato","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2025.101757_bib25","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101757_bib26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","volume":"130","author":"Halperin","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101757_bib27","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","article-title":"Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial","volume":"35","author":"Halvorsen","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.101757_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afac292","article-title":"Optimal stroke preventive strategy for patients aged 80 years or older with atrial fibrillation: a systematic review with traditional and network meta-analysis","volume":"51","author":"Lee","year":"2022","journal-title":"Age Ageing"},{"key":"10.1016\/j.jacadv.2025.101757_bib29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12916-020-01870-w","article-title":"Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial","volume":"18","author":"Wilkinson","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.jacadv.2025.101757_bib30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.amjmed.2017.10.036","article-title":"Clinical outcomes and history of fall in patients with atrial fibrillation treated with oral anticoagulation: insights from the ARISTOTLE Trial","volume":"131","author":"Rao","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.jacadv.2025.101757_bib31","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.7326\/M20-7141","article-title":"Frailty and clinical outcomes of direct oral anticoagulants versus warfarin in older adults with atrial fibrillation: a cohort study","volume":"174","author":"Kim","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacadv.2025.101757_bib32","first-page":"279","article-title":"Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial","volume":"149","author":"Joosten","year":"2024","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.jacadv.2025.101757_bib33","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.amjcard.2017.01.005","article-title":"Relation of stroke and major bleeding to creatinine clearance in patients with atrial fibrillation (from the Fushimi AF Registry)","volume":"119","author":"Abe","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacadv.2025.101757_bib34","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehs274","article-title":"Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"33","author":"Hohnloser","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.101757_bib35","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jacasi.2023.02.002","article-title":"Renal function and clinical outcomes among elderly patients with nonvalvular atrial fibrillation from ANAFIE","volume":"3","author":"Shimizu","year":"2023","journal-title":"JACC Asia"},{"key":"10.1016\/j.jacadv.2025.101757_bib36","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.122.062752","article-title":"Direct oral anticoagulants versus warfarin across the spectrum of kidney function: patient-level network meta-analyses from COMBINE AF","volume":"147","author":"Harrington","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101757_bib37","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.101757_bib38","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacasi.2022.07.008","article-title":"Oral anticoagulants in very elderly nonvalvular atrial fibrillation patients with high bleeding risks: ANAFIE registry","volume":"2","author":"Okumura","year":"2022","journal-title":"JACC Asia"},{"key":"10.1016\/j.jacadv.2025.101757_bib39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/clc.23294","article-title":"A multicenter prospective cohort study to investigate the effectiveness and safety of apixaban in Japanese elderly atrial fibrillation patients (J-ELD AF Registry)","volume":"43","author":"Okumura","year":"2020","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacadv.2025.101757_bib40","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41569-018-0075-z","article-title":"Cognitive dysfunction in atrial fibrillation","volume":"15","author":"Madhavan","year":"2018","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2025.101757_bib41","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014537","article-title":"Cognitive impairment before atrial fibrillation-related ischemic events: neuroimaging and prognostic associations","volume":"9","author":"Banerjee","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2025.101757_bib42","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1007\/s11606-021-06954-8","article-title":"Atrial fibrillation is associated with cognitive impairment, all-cause dementia, vascular dementia, and Alzheimer's disease: a systematic review and meta-analysis","volume":"36","author":"Papanastasiou","year":"2021","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jacadv.2025.101757_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2022-000370","article-title":"Impact of cognitive impairment on clinical outcomes in elderly patients with atrial fibrillation: ANAFIE registry","volume":"5","author":"Nagata","year":"2023","journal-title":"BMJ Neurol Open"},{"key":"10.1016\/j.jacadv.2025.101757_bib44","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11886-018-0975-x","article-title":"Addressing multimorbidity and polypharmacy in individuals with atrial fibrillation","volume":"20","author":"Shaikh","year":"2018","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jacadv.2025.101757_bib45","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015089","article-title":"Polypharmacy, adverse outcomes, and treatment effectiveness in patients \u226575 with atrial fibrillation","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2025.101757_bib46","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.amjcard.2021.03.024","article-title":"Cardiovascular outcomes according to polypharmacy and drug adherence in patients with atrial fibrillation on long-term anticoagulation","volume":"149","author":"Millenaar","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacadv.2025.101757_bib47","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.115.018544","article-title":"Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation","volume":"133","author":"Piccini","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101757_bib48","doi-asserted-by":"crossref","first-page":"H1","DOI":"10.1152\/ajpheart.00702.2020","article-title":"Coronary heart disease and atrial fibrillation: a vicious cycle","volume":"320","author":"Liang","year":"2021","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacadv.2025.101757_bib49","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002587","article-title":"Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF-TIMI48 trial","volume":"5","author":"Xu","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2025.101757_bib50","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101757_bib51","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ahj.2016.05.019","article-title":"Use of concomitant aspirin in patients with atrial fibrillation: findings from the ROCKET AF trial","volume":"179","author":"Shah","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacadv.2025.101757_bib52","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/eurheartj\/eht445","article-title":"Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"35","author":"Alexander","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.101757_bib53","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/CIRCULATIONAHA.119.041296","article-title":"Patients with atrial fibrillation taking nonsteroidal anti-inflammatory drugs and oral anticoagulants in the ARISTOTLE trial","volume":"141","author":"Dalgaard","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101757_bib54","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa2407362","article-title":"Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jacadv.2025.101757_bib55","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.101757_bib56","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.arr.2018.10.006","article-title":"Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation","volume":"49","author":"Kato","year":"2019","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.jacadv.2025.101757_bib57","article-title":"Dose reduction of edoxaban in patients 80 years and older with atrial fibrillation: post hoc analysis of the ENGAGE AF-TIMI 48 randomized clinical trial","volume":"10","author":"Zimerman","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2025.101757_bib58","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/jamacardio.2022.0480","article-title":"Effect of 15-mg edoxaban on clinical outcomes in 3 age strata in older patients with atrial fibrillation: a prespecified subanalysis of the ELDERCARE-AF randomized clinical trial","volume":"7","author":"Kuroda","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2025.101757_bib59","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.28500","article-title":"Outcomes and safety of very-low-dose edoxaban in frail patients with atrial fibrillation in the ELDERCARE-AF randomized clinical trial","volume":"5","author":"Akashi","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacadv.2025.101757_bib60","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031506","article-title":"Efficacy and safety of low-dose edoxaban by body weight in very elderly patients with atrial fibrillation: a subanalysis of the randomized ELDERCARE-AF trial","volume":"13","author":"Akao","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2025.101757_bib61","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1161\/CIRCULATIONAHA.121.057190","article-title":"Efficacy and safety of edoxaban 15 mg according to renal function in very elderly patients with atrial fibrillation: a subanalysis of the ELDERCARE-AF trial","volume":"145","author":"Yoshida","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101757_bib62","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1055\/s-0044-1785511","article-title":"Pharmacokinetics of edoxaban 15 mg in very elderly patients with nonvalvular atrial fibrillation: a subanalysis of the ELDERCARE-AF study","volume":"124","author":"Yamashita","year":"2024","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacadv.2025.101757_bib63","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1161\/HYPERTENSIONAHA.122.19810","article-title":"Home blood pressure can predict the risk for stroke\/bleeding events in elderly patients with nonvalvular atrial fibrillation from the ANAFIE Registry","volume":"79","author":"Kario","year":"2022","journal-title":"Hypertension"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25001747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25001747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T03:56:34Z","timestamp":1750910194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X25001747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2772963X25001747"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.101757","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stroke Prevention With Oral Anticoagulants in High-Risk Atrial Fibrillation in an Aging Population","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.101757","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"101757"}}